pharmaphorum January 14, 2026
Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and validate drug targets and train AI models used in drug discovery.
The first iteration of the disease biology tool, which will be expanded to include five billion cells within three years, was presented for the first time at the JPM Healthcare meeting in San Francisco. Pharma groups AstraZeneca, MSD, and Eli Lilly have partnered with Illumina on the resource.
According to the gene sequencing specialist, the Atlas is already the world’s largest genome‑wide genetic perturbation dataset, currently drawn from sequence data from 150 million cells. It uses CRISPR to switch on and off 20,000 genes across 250 disease-relevant human cell...
Today's Sponsors
Today's Sponsor